ESMO Immuno-Oncology | Poster | Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
To bridge the gap between clinical trial patients and real-world populations, we conducted a comprehensive study in Belgium to characterize cancer patients treated with immune checkpoint inhibitors (ICIs), which have demonstrated survival advantages in various cancer types.
Download our poster, as presented at ESMO Immuno-Oncology 2023, and learn more on the Belgian multicenter study in immuno-oncology.
We present the initial findings of the ICI-treated patient cohort regarding demographic and clinical characteristics, cancer type, ICI treatments, and overall survival (OS).
These initial findings highlight the feasibility of automatically extracting and locally validating federated hospital databases - an invaluable tool for real-world data on ICI-treated patients. Comparable datasets would require linking government databases, which cannot be done in a federated manner nor enriched with hospital-level data.
Ongoing and future analyses will explore:
- Comorbidities
- Tumor staging (TNM)
- Treatment lines
- Adverse events
- Anatomical pathology
- Genetic alterations
- Overall survival
- Time on treatment
- Time to next treatment (rwPFS)
Complete the form above to download the poster and discover the methods used and the first results obtained.
Click HERE to visit our Immuno-Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.
We present the initial findings of the ICI-treated patient cohort regarding demographic and clinical characteristics, cancer type, ICI treatments, and overall survival (OS).
These initial findings highlight the feasibility of automatically extracting and locally validating federated hospital databases - an invaluable tool for real-world data on ICI-treated patients. Comparable datasets would require linking government databases, which cannot be done in a federated manner nor enriched with hospital-level data.
Ongoing and future analyses will explore:
- Comorbidities
- Tumor staging (TNM)
- Treatment lines
- Adverse events
- Anatomical pathology
- Genetic alterations
- Overall survival
- Time on treatment
- Time to next treatment (rwPFS)
Complete the form above to download the poster and discover the methods used and the first results obtained.
Click HERE to visit our Immuno-Oncology Insights overview for more information on the LynxCare datasets within our European hospital network.
